Vivos Therapeutics, Inc.
VVOS
$4.20
-$0.40-8.70%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 26.66% | -18.44% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 26.66% | -18.44% | |||
| Cost of Revenue | 13.47% | -5.87% | |||
| Gross Profit | 39.83% | -28.04% | |||
| SG&A Expenses | 27.03% | 10.32% | |||
| Depreciation & Amortization | 72.88% | 22.92% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 25.25% | 6.61% | |||
| Operating Income | -24.17% | -39.63% | |||
| Income Before Tax | -29.74% | -36.68% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -29.74% | -36.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -29.74% | -36.68% | |||
| EBIT | -24.17% | -39.63% | |||
| EBITDA | -21.87% | -40.53% | |||
| EPS Basic | -22.74% | -14.99% | |||
| Normalized Basic EPS | -22.70% | -15.02% | |||
| EPS Diluted | -22.74% | -14.99% | |||
| Normalized Diluted EPS | -22.70% | -15.02% | |||
| Average Basic Shares Outstanding | 5.72% | 18.84% | |||
| Average Diluted Shares Outstanding | 5.72% | 18.84% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||